JP2013538230A - 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体 - Google Patents

抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体 Download PDF

Info

Publication number
JP2013538230A
JP2013538230A JP2013529139A JP2013529139A JP2013538230A JP 2013538230 A JP2013538230 A JP 2013538230A JP 2013529139 A JP2013529139 A JP 2013529139A JP 2013529139 A JP2013529139 A JP 2013529139A JP 2013538230 A JP2013538230 A JP 2013538230A
Authority
JP
Japan
Prior art keywords
alkyl
independently
another aspect
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013529139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538230A5 (es
Inventor
イソップ チョー，
チョウン キム，
エイドリアン レイ，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013538230(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/885,917 external-priority patent/US7973013B2/en
Priority claimed from US13/050,820 external-priority patent/US8455451B2/en
Application filed by ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2013538230A publication Critical patent/JP2013538230A/ja
Publication of JP2013538230A5 publication Critical patent/JP2013538230A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
JP2013529139A 2010-09-20 2011-03-22 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体 Withdrawn JP2013538230A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/885,917 US7973013B2 (en) 2009-09-21 2010-09-20 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US12/885,917 2010-09-20
US13/050,820 US8455451B2 (en) 2009-09-21 2011-03-17 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US13/050,820 2011-03-17
PCT/US2011/029441 WO2012039791A1 (en) 2010-09-20 2011-03-22 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016006833A Division JP2016074732A (ja) 2010-09-20 2016-01-18 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体

Publications (2)

Publication Number Publication Date
JP2013538230A true JP2013538230A (ja) 2013-10-10
JP2013538230A5 JP2013538230A5 (es) 2014-05-08

Family

ID=47748238

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013529139A Withdrawn JP2013538230A (ja) 2010-09-20 2011-03-22 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
JP2016006833A Withdrawn JP2016074732A (ja) 2010-09-20 2016-01-18 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
JP2017077366A Active JP6475280B2 (ja) 2010-09-20 2017-04-10 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
JP2018173758A Withdrawn JP2019014726A (ja) 2010-09-20 2018-09-18 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016006833A Withdrawn JP2016074732A (ja) 2010-09-20 2016-01-18 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
JP2017077366A Active JP6475280B2 (ja) 2010-09-20 2017-04-10 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
JP2018173758A Withdrawn JP2019014726A (ja) 2010-09-20 2018-09-18 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体

Country Status (21)

Country Link
EP (1) EP2619206A1 (es)
JP (4) JP2013538230A (es)
KR (1) KR101879887B1 (es)
CN (1) CN103108876A (es)
AP (1) AP3699A (es)
AU (1) AU2011306066B2 (es)
BR (1) BR112013008017A2 (es)
CA (1) CA2807496C (es)
CL (1) CL2013000727A1 (es)
CO (1) CO6680669A2 (es)
CR (1) CR20130172A (es)
EA (1) EA026523B1 (es)
EC (1) ECSP13012560A (es)
IL (1) IL225221A0 (es)
MA (1) MA34593B1 (es)
MX (1) MX2013003179A (es)
NZ (1) NZ608070A (es)
PE (3) PE20131165A1 (es)
SG (1) SG188223A1 (es)
WO (1) WO2012039791A1 (es)
ZA (1) ZA201301042B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523169A (ja) * 2014-07-28 2017-08-17 ギリアード サイエンシーズ， インコーポレイテッド 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ［３，２−ｄ］ピリミジン、フロ［３，２−ｄ］ピリミジン、およびピロロ［３，２−ｄ］ピリミジン

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101645742B1 (ko) 2008-04-23 2016-08-04 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료를 위한 카바-뉴클레오사이드 유사체
SI2480559T1 (sl) 2009-09-21 2013-10-30 Gilead Sciences, Inc. Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov
ES2524398T3 (es) 2010-07-19 2014-12-09 Gilead Sciences, Inc. Métodos para la preparación de profármacos de fosforoamidato diastereoméricamente puros
WO2012012776A1 (en) 2010-07-22 2012-01-26 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
JP5891241B2 (ja) 2010-12-20 2016-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｃｖを処置するための組合せ
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
SG10201706949VA (en) 2013-01-31 2017-09-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
CN104230985B (zh) * 2014-09-01 2017-01-18 北京天弘天达医药科技有限公司 (s)‑2‑[(s)‑(4‑硝基‑苯氧基)‑苯氧基‑磷酰基氨基]丙酸异丙酯的制备方法
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
HUE056470T2 (hu) 2014-12-26 2022-02-28 Univ Emory Vírusellenes N4-Hidroxicitidin származékok
CN114366745A (zh) 2015-09-16 2022-04-19 吉利德科学公司 治疗沙粒病毒科和冠状病毒科病毒感染的方法
KR102460968B1 (ko) 2017-03-14 2022-11-01 길리애드 사이언시즈, 인코포레이티드 고양이 코로나바이러스 감염의 치료 방법
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
TW201919648A (zh) 2017-07-11 2019-06-01 美商基利科學股份有限公司 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
GB2590198B (en) 2017-12-07 2022-02-23 Univ Emory N4-hydroxycytidine derivatives and anti-viral uses related thereto
TW202313067A (zh) 2020-01-27 2023-04-01 美商基利科學股份有限公司 治療sars cov-2感染之方法
JP2023516087A (ja) 2020-03-12 2023-04-17 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
CN115362004A (zh) 2020-04-06 2022-11-18 吉利德科学公司 1’-氰基取代的碳核苷类似物的吸入制剂
JP2023528810A (ja) 2020-05-29 2023-07-06 ギリアード サイエンシーズ， インコーポレイテッド レムデシビル治療方法
KR20230028486A (ko) 2020-06-24 2023-02-28 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오시드 유사체 및 이의 용도
TW202228722A (zh) 2020-08-27 2022-08-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法
WO2023167944A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2023207942A1 (zh) * 2022-04-25 2023-11-02 北京沐华生物科技有限责任公司 用于治疗或预防冠状病毒感染的核苷类药物及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520367A (ja) * 2001-01-22 2004-07-08 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
JP2006526629A (ja) * 2003-05-30 2006-11-24 ファーマセット，インク． 修飾されたフッ化ヌクレオシド類似体
JP2008517912A (ja) * 2004-10-21 2008-05-29 メルク エンド カムパニー インコーポレーテッド ＲＮＡ依存性ＲＮＡウイルス感染治療用フッ素化ピロロ［２，３−ｄ］ピリミジンヌクレオシド
WO2009132123A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
US20100203015A1 (en) * 2009-02-10 2010-08-12 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
JP2013505265A (ja) * 2009-09-21 2013-02-14 ギリード・サイエンシズ・インコーポレーテッド 抗ウイルス治療のための２′−フルオロ置換カルバ−ヌクレオシド類似体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DK0533833T3 (da) 1990-06-13 1996-04-22 Arnold Glazier Phosphorprolægemidler
DE69129650T2 (de) 1990-09-14 1999-03-25 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
WO2001032153A2 (en) 1999-11-04 2001-05-10 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1296690A2 (en) 2000-02-18 2003-04-02 Shire Biochem Inc. METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS USING NUCLEOSIDE ANALOGUES
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
CN101862345B (zh) 2000-10-18 2014-06-04 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
EP1438054A4 (en) 2001-09-28 2006-07-26 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8431695B2 (en) 2005-11-02 2013-04-30 Bayer Intellectual Property Gmbh Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US8440813B2 (en) 2007-01-12 2013-05-14 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
US8188272B2 (en) 2007-03-21 2012-05-29 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008141079A1 (en) 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520367A (ja) * 2001-01-22 2004-07-08 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
JP2006526629A (ja) * 2003-05-30 2006-11-24 ファーマセット，インク． 修飾されたフッ化ヌクレオシド類似体
JP2008517912A (ja) * 2004-10-21 2008-05-29 メルク エンド カムパニー インコーポレーテッド ＲＮＡ依存性ＲＮＡウイルス感染治療用フッ素化ピロロ［２，３−ｄ］ピリミジンヌクレオシド
WO2009132123A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
WO2009132135A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
US20100203015A1 (en) * 2009-02-10 2010-08-12 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
JP2013505265A (ja) * 2009-09-21 2013-02-14 ギリード・サイエンシズ・インコーポレーテッド 抗ウイルス治療のための２′−フルオロ置換カルバ−ヌクレオシド類似体
JP5795766B2 (ja) * 2009-09-21 2015-10-14 ギリード・サイエンシズ・インコーポレーテッド 抗ウイルス治療のための２′−フルオロ置換カルバ−ヌクレオシド類似体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523169A (ja) * 2014-07-28 2017-08-17 ギリアード サイエンシーズ， インコーポレイテッド 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ［３，２−ｄ］ピリミジン、フロ［３，２−ｄ］ピリミジン、およびピロロ［３，２−ｄ］ピリミジン
JP2020023590A (ja) * 2014-07-28 2020-02-13 ギリアード サイエンシーズ， インコーポレイテッド 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ［３，２−ｄ］ピリミジン、フロ［３，２−ｄ］ピリミジン、およびピロロ［３，２−ｄ］ピリミジン
JP6991188B2 (ja) 2014-07-28 2022-01-12 ギリアード サイエンシーズ， インコーポレイテッド 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ［３，２－ｄ］ピリミジン、フロ［３，２－ｄ］ピリミジン、およびピロロ［３，２－ｄ］ピリミジン

Also Published As

Publication number Publication date
CO6680669A2 (es) 2013-05-31
EA026523B1 (ru) 2017-04-28
AP2013006767A0 (en) 2013-03-31
AP3699A (en) 2016-05-31
CL2013000727A1 (es) 2013-08-23
KR20130110168A (ko) 2013-10-08
JP2017119726A (ja) 2017-07-06
SG188223A1 (en) 2013-04-30
PE20230684A1 (es) 2023-04-21
MX2013003179A (es) 2013-04-24
MA34593B1 (fr) 2013-10-02
AU2011306066A1 (en) 2013-02-28
PE20131165A1 (es) 2013-10-14
CR20130172A (es) 2013-05-29
CA2807496C (en) 2019-01-22
KR101879887B1 (ko) 2018-07-18
JP2019014726A (ja) 2019-01-31
CA2807496A1 (en) 2012-03-29
ZA201301042B (en) 2014-07-30
EA201390141A1 (ru) 2013-09-30
CN103108876A (zh) 2013-05-15
JP6475280B2 (ja) 2019-02-27
JP2016074732A (ja) 2016-05-12
IL225221A0 (en) 2013-06-27
AU2011306066B2 (en) 2015-01-29
EP2619206A1 (en) 2013-07-31
WO2012039791A1 (en) 2012-03-29
ECSP13012560A (es) 2013-06-28
BR112013008017A2 (pt) 2016-06-14
PE20171624A1 (es) 2017-11-02
NZ608070A (en) 2015-11-27

Similar Documents

Publication Publication Date Title
JP6475280B2 (ja) 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
AU2020202600B2 (en) 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EA046452B1 (ru) 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160127

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160129